Oxford Ledge
Search
Dermata Therapeutics, Inc. (NASDAQ: DRMA) is a biotechnology company trading at $1.20. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:43 UTC.
Dermata Therapeutics is a skincare company that began by researching prescription products for skin conditions, with its lead asset XYNGARI achieving statistically significant results in a Phase 3 clinical trial for moderate-to-severe acne. In September 2025, the company shifted strategy away from the prescription drug pathway toward developing and selling direct-to-consumer and business-to-business cosmetic and over-the-counter skincare products.
Summarized from Dermata Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Quote | |
| Price | $1.20 |
| Volume | 2.4K shares |
Dermata Therapeutics is a skincare company that began by researching prescription products for skin conditions, with its lead asset XYNGARI achieving statistically significant results in a Phase 3 clinical trial for moderate-to-severe acne.
DRMA trades at $1.20, as of 2026-10-11.
Dermata Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-08-17. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:43 UTC. This page is also available as JSON at /api/data?ticker=DRMA and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for DRMA and 5,000+ tickers.
Create a free account — keep DRMAGET /api/data?ticker=DRMA
This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt